Want to see PAHC full AI Analyst Report?
Adjusted EBITDA by Segment
Reports segment-level operating profitability after adjusting for one-time items, revealing which business units generate cash, which have the strongest margins, and where cost structure or scale could support future earnings growth.Animal Health has become the primary EBITDA engine—sustained, accelerating margin expansion driven by new MFA products, vaccines and mix gains, and underpins management's raised guidance. Mineral Nutrition is growing top-line but shows margin compression, so its EBITDA contribution remains modest. Performance Products is a clear drag, with steep declines that could cap consolidated EBITDA until demand recovers or the business is resized. Upsized credit and stronger guidance improve confidence, but Brazil antimicrobial rules, FX/interest headwinds and inventory build-up risk trimming gains into FY2027.
Date | Animal Health | Mineral Nutrition | Performance Products |
|---|---|---|---|
Jun 30, 2026 | $75.40M | $5.60M | $3.40M |
Mar 31, 2026 | $71.10M | $5.14M | $2.22M |
Dec 31, 2025 | $82.17M | $6.37M | $831.00K |
Sep 30, 2025 | $74.87M | $4.52M | $1.60M |
Jun 30, 2025 | $60.58M | $5.61M | $3.04M |
Mar 31, 2025 | $63.12M | $5.76M | $3.34M |
Dec 31, 2024 | $58.18M | $5.70M | $1.89M |
Sep 30, 2024 | $40.38M | $3.76M | $2.29M |
Jun 30, 2024 | $41.29M | $5.40M | $3.06M |
Mar 31, 2024 | $36.52M | $4.67M | $2.37M |